Symptomatic overlap between irritable bowel syndrome and microscopic colitis†
David Limsui MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorCorresponding Author
Darrell S. Pardi MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
200 First Street, SW, Rochester, Minnesota 55905Search for more papers by this authorMichael Camilleri MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorEdward V. Loftus Jr. MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorPatricia P. Kammer CCRP
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorWilliam J. Tremaine MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorWilliam J. Sandborn MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorDavid Limsui MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorCorresponding Author
Darrell S. Pardi MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
200 First Street, SW, Rochester, Minnesota 55905Search for more papers by this authorMichael Camilleri MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorEdward V. Loftus Jr. MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorPatricia P. Kammer CCRP
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorWilliam J. Tremaine MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorWilliam J. Sandborn MD
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
Search for more papers by this authorPresented at 2005 Digestive Disease Week meeting, Chicago, IL and published in abstract form (Gastroenterology 2005;128:A331).
Abstract
Background: Microscopic colitis is diagnosed on the basis of histologic criteria, and irritable bowel syndrome (IBS) is diagnosed by symptom-based criteria. There has been little investigation into the symptomatic overlap between these conditions. Our aim was to assess the prevalence of symptoms of irritable bowel syndrome in a population-based cohort of patients with microscopic colitis.
Methods: The Rochester Epidemiology Project (REP), a medical records linkage system providing all health care data for the defined population of Olmsted County, Minnesota, was used to identify all county residents with a diagnosis of microscopic colitis between 1985 and 2001. The medical records of these individuals were reviewed to ascertain symptoms consistent with Rome, Rome II, and Manning criteria for irritable bowel syndrome.
Results: One hundred thirty-one cases of microscopic colitis were identified. Median age at diagnosis was 68 years (range, 24–95); 71% were women. Sixty-nine (53%) and 73 (56%) met Rome and Rome II criteria for irritable bowel syndrome, respectively. Fifty-four (41%) had three or more Manning criteria. Forty-three (33%) had previously been diagnosed with irritable bowel syndrome.
Conclusions: In this population-based cohort of histologically confirmed microscopic colitis, approximately one-half met symptom-based criteria for the diagnosis of irritable bowel syndrome. The clinical symptom-based criteria for irritable bowel syndrome are not specific enough to rule out the diagnosis of microscopic colitis. Therefore, patients with suspected diarrhea-predominant irritable bowel syndrome should undergo biopsies of the colon to investigate for possible microscopic colitis if symptoms are not well controlled by antidiarrheal therapy.
(Inflamm Bowel Dis 2006)
REFERENCES
- 1 Pardi DS, Ramnath VR, Loftus EV Jr, et al. Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol. 2002; 97: 2829–2833.
- 2 Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut. 1996; 39: 846–851.
- 3 Baert F, Wouters K, D'Haens G, et al. Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut. 1999; 45: 375–381.
- 4 Fernandez-Banares F, Salas A, Esteve M, et al. Collagenous and lymphocytic colitis: evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am J Gastroenterol. 2003; 98: 340–347.
- 5 Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut. 2004; 53: 536–541.
- 6 Pardi DS. Microscopic colitis: an update. Inflamm Bowel Dis. 2004; 10: 860–870.
- 7 Fernandez-Banares F, Salas A, Forne M, et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol. 1999; 94: 418–423.
- 8 Fine KD, Seidel RH, Do K. The prevalence, anatomic distribution, and diagnosis of colonic causes of chronic diarrhea. Gastrointest Endosc. 2000; 51: 318–326.
- 9 Shah RJ, Fenoglio-Preiser C, Bleau BL, et al. Usefulness of colonoscopy with biopsy in the evaluation of patients with chronic diarrhea. Am J Gastroenterol. 2001; 96: 1091–1095.
- 10 Yusoff IF, Ormonde DG, Hoffman NE. Routine colonic mucosal biopsy and ileoscopy increases diagnostic yield in patients undergoing colonoscopy for diarrhea. J Gastroenterol Hepatol. 2002; 17: 276–280.
- 11 Patel Y, Pettigrew NM, Grahame GR, et al. The diagnostic yield of lower endoscopy plus biopsy in nonbloody diarrhea. Gastrointest Endosc. 1997; 46: 338–343.
- 12 Pardi DS, Loftus EV, Smyrk TC, et al. The epidemiology of microscopic colitis: a population-based study in Olmsted County, MN ( Gut. 2007 in press).
- 13 Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002; 123: 2108–2131.
- 14 Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ. 1978; 2: 653–654.
- 15 Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int. 1989; 2: 92–95.
- 16 Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999; 45: 43–47.
- 17 Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002; 97: S7–S26.
- 18 Mullhaupt B, Guller U, Anabitarte M, et al. Lymphocytic colitis: clinical presentation and long term course. Gut. 1998; 43: 629–633.
- 19 Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71: 266–274.
- 20 Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am. 1981; 245: 54–63.
- 21 Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002; 97: 1910–1915.
- 22 Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002; 122: 1778–1783.
- 23 Tuncer C, Cindoruk M, Dursun A, et al. Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome. Acta Gastroenterol Belg. 2003; 66: 133–136.
- 24 Bertomeu A, Ros E, Barragan V, et al. Chronic diarrhea with normal stool and colonic examinations: organic or functional? J Clin Gastroenterol. 1991; 13: 531–536.
- 25 Robinson RJ, Stone M, Mayberry JF. Normal rectal mucosa. Should we biopsy? Hepatogastroenterology. 1997; 44: 703–705.
- 26 Marshall JB, Singh R, Diaz-Arias AA. Chronic, unexplained diarrhea: are biopsies necessary if colonoscopy is normal? Am J Gastroenterol. 1995; 90: 372–376.
- 27 MacIntosh DG, Thompson WG, Patel DG, et al. Is rectal biopsy necessary in irritable bowel syndrome? Am J Gastroenterol. 1992; 87: 1407–1409.
- 28 Thompson WG. Should a normal-appearing colorectal mucosa be biopsied? Am J Gastroenterol. 1995; 90: 336–337.
- 29 Carpenter HA, Tremaine WJ, Batts KP, et al. Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci. 1992; 37: 1903–1909.
- 30 Goff JS, Barnett JL, Pelke T, et al. Collagenous colitis: histopathology and clinical course. Am J Gastroenterol. 1997; 92: 57–60.
- 31 Tanaka M, Mazzoleni G, Riddell RH. Distribution of collagenous colitis: utility of flexible sigmoidoscopy. Gut. 1992; 33: 65–70.
- 32 Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol. 1999; 94: 2912–2917.
- 33 Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002; 97: 2812–2819.
- 34 Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002; 123: 1972–1979.
- 35 Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004; 53: 1096–1101.
- 36 O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000; 12: 449–457.
- 37 Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996; 347: 150–153.
- 38 Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997; 314: 779–782.
- 39 McKendrick MW. Post Salmonella irritable bowel syndrome-5 year review. J Infect. 1996; 32: 170–171.
- 40 Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. 1999; 318: 565–566.
- 41 Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003; 98: 1578–1583.
- 42 Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000; 47: 804–811.
- 43 Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003; 125: 1651–1659.
- 44 Read M, Read NW, Barber DC, et al. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci. 1982; 27: 807–814.
- 45 Amaro R, Poniecka A, Rogers AI. Collagenous colitis treated successfully with bismuth subsalicylate. Dig Dis Sci. 2000; 45: 1447–1450.
- 46 Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology. 1998; 114: 29–36.
- 47 Bonderup OK, Hansen JB, Birket-Smith L, et al. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut. 2003; 52: 248–251.
- 48 Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology. 2002; 123: 978–984.
- 49 Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology. 2002; 122: 20–25.
- 50 Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000; 355: 1035–1040.
- 51 Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000; 14: 23–34.
- 52 Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000; 108: 65–72.
- 53 Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 1995; 40: 86–95.
- 54 Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am. 1990; 74: 21–28.
- 55 Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am. 2005; 34: 235–245.
- 56 Isgar B, Harman M, Kaye MD, et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut. 1983; 24: 190–192.
- 57 Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004; 49: 469–474.
- 58 Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002; 97: 389–396.